RxDoctor Payments Data

Hilary Puzak, APRN

Psychiatric/Mental Health · Greensboro, NCNPI 1659004927

Payments from drug & device makers

$2,162in general payments, 2019–2025

Across 132 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$536
  • AbbVie$515
  • Johnson & Johnson$324
  • Teva Pharmaceuticals USA, Inc.$203
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$117
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$98
  • plus $369 from 12 others

What the payments were for

  • Food & beverage$2,162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,162 in reported general payments places this provider in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$8,900
Medicare patients
38
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine18$163,887
Invega SustennaPaliperidone Palmitate41$153,894
VraylarCariprazine Hcl66$115,778
Abilify MaintenaAripiprazole24$70,523
RexultiBrexpiprazole39$58,821
AristadaAripiprazole Lauroxil16$48,259
FanaptIloperidone16$29,214
LybalviOlanzapine/Samidorphan Malate12$18,248
Lurasidone Hcl33$16,864
Clozapine41$7,574
Paliperidone ErPaliperidone29$3,574
Atomoxetine Hcl20$3,084
Duloxetine Hcl161$3,003
Buspirone Hcl170$2,683
Aripiprazole67$2,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$203$163,88718 claims
Johnson & JohnsonInvega Sustenna$324$153,89441 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$34$129,34463 claims
AbbVieVraylar$515$115,77866 claims
Alkermes, Inc.Aristada, Lybalvi$536$66,50728 claims
Vanda Pharmaceuticals Inc.Fanapt$24$29,21416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →